Tech Lead sold all of his Bitcoin

The speaker reacts to a Tech Lead video in which Tech Lead says 'I sold all of my Bitcoin' after being 'over leveraged' and staring down liquidation; he frames that sale as an emotional, survival choice rather than a signal that Bitcoin itself is definitively broken. Tech Lead repeatedly stresses Bitcoin's dependence on attention, summarised as 'No earnings, no yield, no press releases'—meaning price action depends on new buyers and public chatter more than cash flows.

Tech Lead lists concrete near‑term and structural risks: two 'ticking time bombs'—first, quantum computing as a speculative threat; second, miner economics because '95% of all Bitcoin is already minted' and the expected fee economy never materialised, so declining fees could reduce miner incentives and security. He also raises liquidity and concentration risks (citing large holders such as MicroStrategy as potentially market‑moving), and recalls earlier worries about 'Tether' manipulation. He notes real‑world safety problems from attention‑driven wealth posting—'72 attacks worldwide in 2025'—and prefers not to custody private keys on devices like 'Ledger' or 'Trezor'.

Practically, Tech Lead favours simpler exposure via a 'Bitcoin ETF' and 'dollar cost average', citing tax and custody friction (example: moving a 2016 Coinbase purchase between wallets complicates cost basis). He recommends modest, budgeted allocations—'a few percent', "fun money", or money you can lose—rather than going 100% long; diversify into index funds and keep a long time horizon (he references cohorts like '2032' and the 2021 rediscovery cycles). A snapshot price in the video is given as $66,601.32, and historical volatility is evoked with '20K last October to the low 60K this summer, a 50% crash'.

Bottom line: Tech Lead sold to survive a leveraged position and lists attention, liquidity concentration, quantum and miner fee risks as reasons for caution; he nevertheless views Bitcoin as a technology that gets 'rediscovered' cyclically and recommends small, patient allocations via an ETF if one chooses exposure.